PTC Therapeutics: Underwriters exercise option to purchase 600,00 shares
PTC Therapeutics announced that the underwriters of its previously announced public offering of 4M shares of its common stock, which closed on April 3, 2018, have exercised in full their option to purchase an additional 600,000 shares at the public offering price less underwriting discounts and commissions. After giving effect to the closing with respect to the additional shares, the total number of shares sold by PTC in the offering increased to 4.6M shares. All of the shares in the offering were sold by PTC. PTC's aggregate net proceeds from the offering are expected to be approximately $117.9M, after deducting underwriting discounts and commissions and estimated offering expenses. Credit Suisse and Citigroup acted as lead book-running managers for the offering. RBC Capital Markets also acted as a book-running manager.